Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine by Frew, Paula M. et al.
Environmental & Occupational Health Faculty 
Publications Environmental and Occupational Health 
4-15-2013 
Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment 
Outcomes Associated with a Randomized Controlled Double-Blind 
Trial of a Live Attenuated Yellow Fever Vaccine 
Paula M. Frew 
University of Nevada, Las Vegas, paula.frew@unlv.edu 
Eve T. Shapiro 





Harry L. Keyserling 
Emory University 
See next page for additional authors 
Follow this and additional works at: https://digitalscholarship.unlv.edu/env_occ_health_fac_articles 
 Part of the Immunology of Infectious Disease Commons, and the Virology Commons 
Repository Citation 
Frew, P. M., Shapiro, E. T., Lu, L., Edupuganti, S., Keyserling, H. L., Mulligan, M. J. (2013). Enrollment in YFV 
Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-
Blind Trial of a Live Attenuated Yellow Fever Vaccine. Tropical Medicine and Surgery, 1(3), 1-7. 
http://dx.doi.org/10.4172/2329-9088.1000117 
This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV 
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the 
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from 
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself. 
 
This Article has been accepted for inclusion in Environmental & Occupational Health Faculty Publications by an 
authorized administrator of Digital Scholarship@UNLV. For more information, please contact 
digitalscholarship@unlv.edu. 
Authors 
Paula M. Frew, Eve T. Shapiro, Lu Lu, Srilatha Edupuganti, Harry L. Keyserling, and Mark J. Mulligan 
This article is available at Digital Scholarship@UNLV: https://digitalscholarship.unlv.edu/env_occ_health_fac_articles/
401 
Research Article Open Access
Frew et al., Trop Med Surg 2013, 1:3
DOI: 10.4172/2329-9088.1000117
search Article Open Access
Volume 1 • Issue 3 • 1000117Trop Med Surg, an open access journal ISSN: 2329-9088
Keywords: Yellow fever vaccine; Immunization; Clinical trials;
Willingness to participate; Ethnic minorities; Women
Introduction
Ensuring proportional representation of diverse populations 
in vaccine trials is an ethical and a scientific imperative in clinical 
research. The NIH Health Revitalization Act of 1993 underscored the 
importance of inclusion of women and minorities in research studies 
as a national policy objective to fulfill broad social justice aims, to 
promote generalizability of study findings, and to understand subgroup 
differences in health outcomes [1].
Involvement of diverse groups in vaccine clinical trials is critical for 
meaningful evaluation of vaccine products and to achieve overarching 
public health objectives. Women and minorities have historically 
remained underrepresented in clinical research studies [2,3]. A high 
level of mistrust about the medical system, vaccine safety issues, and 
misperceptions about vaccines may factor in the decision to join a 
clinical study and encourage others to receive immunizations in the 
future [4-8]. The legacy of the Tuskegee syphilis study also serves as 
a source of medical establishment mistrust [8,9]. However, greater 
participation of minorities in biomedical research has been achieved 
in recent years [10].
Monitoring recruitment outcomes is an essential practice for 
successful enrollment of diverse populations [11]. The development 
and implementation of dynamic tracking systems provides detail 
on subject accrual patterns [12], along with insight on recruitment 
approaches that yield desired outcomes [13]. A system was developed 
by our site in collaboration with a team of biostatisticians and 
computer programmers to provide dynamic evaluative monitoring and 
assessment of a yellow fever virus vaccine study [14]. Previous findings 
have indicated that “willingness-to-participate” (WTP) declines with 
the passage of time among groups [15-17]. Thus, factors that affect the 
attrition of target populations in clinical studies are also of interest to 
ensure that future enrollment goals are met.
The purpose of this study is to investigate factors associated with 
accrual of women and minorities from prerandomization to enrollment 
stages. Although much is known about the enormous challenges 
associated with recruitment and retention of populations in other 
types of health research [18-20] very little is known about the factors 
which impact the ability to enroll a diverse group of participants in 
vaccine safety studies [21-26]. Participant concerns in this arena extend 
beyond clinical trials to vaccine safety issues and other immunization 
fears (e.g., needles) [27].
Background on yellow fever immunization
Since its introduction in the 1930s the yellow fever vaccine has 
been considered one of the most effective and safest vaccines available 
to prevent infection with the potentially fatal flavivirus [28,29]. At 
least 500 million doses have been made available globally and the US 
Centers for Disease Control and Prevention (CDC) and the World 
Health Organization (WHO) recommend vaccination for persons ≥ 9 
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months of age who are traveling to or living in a yellow fever endemic 
area [28,30] However, recent reports of adverse events after yellow 
fever vaccine (17-D and 17-DD) have raised concern about its safety 
[31,32].
Our clinical research site conducted a double-blind, randomized 
outpatient study to determine if human Immune Globulin (IG) 
limits the viremic response to 17D yellow fever vaccine without 
compromising immunogenicity [33]. The hypothesis examined whether 
co-administration of yellow fever antibody and yellow fever vaccine 
(passive-active immunization) resulted in effective immunization. 
The clinical study was conducted in 80 healthy adults who were 
18-40 years of age. A stratified randomization procedure was used 
to ensure equal distribution of study medications to participants by 
gender and race. 
The recruitment study
We evaluated the sociodemographic and recruitment factors 
predictive of enrollment in this phase IV yellow fever vaccine clinical 
trial. More specifically, we examined differences in the enrollment 
patterns of a diverse sample of women and minorities. We sought 
to contribute to the evidence for the need for culturally sensitive 
approaches in the recruitment process by investigating potential 
disparities in enrollment at our site. For example, clinical screening 
processes can be enhanced through cultural competency trainings 
for research team members. Trainings would offer communication 
strategies sensitive to cultural beliefs, values, and needs of participants.
We also examined the role of our Integrated Marketing 
Communication (IMC) approach on the recruitment process to 
determine whether specific approaches had an effect on the enrollment 
outcome [34]. The IMC strategy focuses on key communication 
objectives (e.g., build study awareness) for target audiences with a 
campaign comprised of various approaches. Over time, the interaction 
of such tactics theoretically would generate sufficient study interest 
among priority groups to realize enrollment goals. Thus, IMC posits 
that an equilibrium of effect can be anticipated with the counteraction 
of advertising and promotional tactics over time [34].
Methods
Study sample
From May 2005 through June 2007 volunteers were actively 
recruited for a randomized, controlled, double-blind trial of comparative 
viremia, immunogenicity and safety of an attenuated yellow fever virus 
vaccine when given alone or in combination with human immune 
globulin [33]. Recruitment strategies focused on print materials such 
as flyers and posters; electronic resources such as websites, emails, 
and list-serves; and mass media outlets including newspaper ads. Of 
the 210 recruitment tactics employed, 42.38% involved direct outreach 
with interpersonal contacts and distribution of print materials to these 
contacts, 24.76% involved flyers and print materials, 20.0% involved 
mass media recruitment strategies, and the remaining tactics focused 
on electronic/internet awareness building (12.86%). Recruitment 
strategies targeted specific populations including college and graduate 
students, missionaries in need of the yellow fever vaccine for travel, 
and healthcare providers able to encourage patients’ participation 
and inoculation prior to travel to yellow fever endemic regions of the 
world. To avoid selection bias via our recruitment strategies, we widely 
advertised the study in places where diverse racial and ethnic groups 
of persons would be in need of yellow fever vaccination for travel 
purposes. Therefore we conducted outreach and advertised the study 
in a variety of community settings such as churches, travel clinics, and 
colleges and universities.
Most often, potential volunteers contacted the study site by a 
telephone hotline from which our staff was available to provide 
preliminary information about the study and to conduct a brief pre-
screening for eligibility. Occasionally, volunteers walked in to study 
site, and the pre-screen was performed in person. Eligible volunteers 
were referred to study nurses for initiation of the informed consent 
process and clinical screening. For a consenting volunteer, once clinical 
screening was completed successfully, she/he was able enroll in the 
study. Potential volunteers who could not be contacted after three 
un-returned phone calls were considered to have lost interest in study 
participation. 
For this vaccine study, inclusion and exclusion criteria were 
established by the study protocol. Eligible potential volunteers had the 
following characteristics (additional inclusion/exclusion criteria are 
listed at www.clinical trials.gov [NCT00254826]):
• Between 18 and 40 years old.
• Could understand and sign informed consent and HIPAA 
authorization forms.
• No history of allergic reaction to the vaccine, vaccine components, 
human immune globulin, eggs, or vaccines prepared in eggs or chick 
embryo cultures (e.g., influenza, measles).
• HIV, hepatitis B, and hepatitis C negative.
• Healthy, with no major medical problems including a history of 
cancer, immunodeficiency or any other medical condition that might 
have endangered the health or safety of the volunteer.
• No history of previous yellow fever, West Nile, dengue, St. 
Louis encephalitis, Japanese encephalitis, or tick-borne encephalitis 
vaccination or infection.
• No history of travel to yellow fever endemic zones as defined by 
the Centers for Disease Control and Prevention.
• Weighed more than 110 pounds at screening
• For female volunteers, not pregnant and agreed to use effective 
birth control throughout the duration of study.
Data collection
During pre-screening, potential volunteers consented to the 
inclusion of contact information, demographic characteristics, and 
psycho-social factors in a volunteer database. Information collected 
included name, address, phone numbers, email address, age, 
gender, race/ethnicity, education, sexual orientation, motivation for 
participation and means of recruitment. Potential volunteers were 
permitted to skip any questions that they did not feel comfortable 
answering. Data were stored in a password protected, numerically 
encoded online volunteer database. Pre-screening took place during 
normal business hours when a potential volunteer contacted the study 
site.
Measurement
The primary outcome of interest in this analysis was enrollment 
in the clinical trial. Alternative outcomes included ineligible, lost to 
follow up, or eligible but not enrolled (i.e., passive or active refusal of 
participation). Educational attainment included the following levels: 
K-12 grade or some College (Vocational or technical training, some 
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college without degree, or Associate degree), and Bachelor's degree or 
beyond (Bachelor’s degree, Masters, Doctorate or Professional degree). 
Race/ethnicity included ‘white’ for those who self-identified as white/
Caucasian respondents, ‘Non-white’ for those reporting other than 
white race including Black/African American, Hispanic/Latino/a, 
Asian/Pacific Islander, Multiracial or ‘Other’ race or ethnicity. 
Recruitment tactics were categorized as general promotion (print 
material distribution, educational presentations, special community 
events, word of mouth referral and multiple sources), internet-based 
(email, listservs, web banners), and mass media (television, radio, mass 
print advertising).
Statistical analysis
SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA) and SPSS 
version 15.0 (SPSS, Inc., Chicago, IL., USA) were used for analyses. 
Descriptive statistics and cross-tabulations were generated for all of the 
variables of interest. An overall multivariate model (i.e., binary logit 
regression method) was performed along with similar analyses for 
the male subgroup. Participant motivation had a large proportion (≥ 
35%) of missing data and therefore was not included in the regression 
analyses. Significant independent predictors of outcomes were 
assessed at p <0.05 levels. Differences in categorical sociodemographic 
information (e.g., gender and enrollment status) were assessed by Chi-
square (χ2) tests and differences in continuous information (e.g., mean 
age) were assessed by paired t-tests (t). 
Descriptive statistics were generated from the recruitment 
campaign records. These tactics were catalogued and continuously 
updated in a spreadsheet that detailed the target audience (community 
segment), date of activity, communication approach tactic, and 
associated recruitment strategies. Each tactic was coded (e.g., 1, 2, 3) 
to enumerate the campaign approach frequencies. Cross-tabulation 
procedures including chi-square (χ2) tests were employed to assess the 
differences in recruitment sources and enrollment outcomes for all 
participants and for minorities.
Results
Volunteer contacts, screening and enrollment
Of those individuals who initially contacted the study site (N=355), 
88.7% (n=315) completed the pre-screening process (Figure 1). The 
remaining 40 potential volunteers either lost interest prior to pre-
screening or were unable to be contacted. Of those individuals who 
completed the telephone pre-screen, 17.7% (n=56) were found to be 
ineligible for a variety of reasons including age, difficulty with study 
commitment, HIV positive status or other medical exclusion, and risk 
ineligibility through upcoming travel to endemic areas (Table 2). The 
remaining 259 potential volunteers were referred to the clinical nursing 
staff for clinical screening and informed consent processes. 
Of these 259 pre-screened and potentially eligible volunteers, 
53.2% (n=138) did not complete clinical screening. Many of these 
participants were unable to be contacted or lost interest prior to 
completing clinical screening, often because of an unpredicted time 
delay between volunteer’s initial contact and actual opportunity for 
enrollment. Ten volunteers were enrolled at two sites each month 
and many potential volunteers lost interest while waiting in queue. 
121 individuals completed informed consent and clinical screening, 
however 28 individuals were found to be ineligible (Table 3). Of the 
remaining 93 individuals, 80 volunteers (86.0%) enrolled in the yellow 
fever vaccine clinical trial. 
Characteristics of the sample
The study population (Table 1) was created to characterize the 
differences between volunteers who enrolled in the trial (n=80) and 
volunteers who did not enroll (n=151). The non-enrolling groups is 
comprised of both the group of eligible volunteers who completed the 
clinical screening, but did not to enroll (n=13) as well as the group 
of potentially eligible volunteers who chose not to complete clinical 
screening (n=138). 
Participants in the enrolled group were more often women (56.3%, 
n=45) and most reported heterosexual orientation (87.8%, n=65 out of 
74, excluded missing data). Nearly three-fourths (72.5%, n=58) of the 
enrolled participants reported white race, while less than one quarter 
(20.0%, n=16) reported race other than white or Hispanic ethnicity 
(7.5%, n=6). Education was not normally distributed with most 
volunteers having a “high” education level (BA, Masters, Doctorate 
or Professional degree, 68.4%, n=52 out of 76, excluded missing 
data), reflecting the large push for recruitment among college and 
graduate students. Many volunteers reported desire for compensation 
and vaccine (26.0%, n=20 out of 77, excluded missing data) as their 
motivation for participating in this yellow fever vaccine clinical trial and 
many reported directed outreach strategies such as flyers, community 
events, and health fairs (59.0%, n=46 out of 78, excluded missing data) 
were responsible for recruiting them to the study site.
Figure 1: Flow chart of participant counts through screening and eligibility 
steps.
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Recruitment tactics
The campaign totaled 210 tactics implemented throughout the 
recruitment cycle at our site. General promotional activities including 
in-person outreach to faith leaders and their communities, educational 
presentations, and special events comprised a significant proportion 
of the recruitment endeavor (n=89 tactics; 42.38% of campaign 
approach). Print materials were also distributed (n=52 tactics; 24.76% 
of overall endeavor). Effort given to web-based recruitment (e.g., email 
outreach, listserv and web advertising) resulted in about 12.86% of 
the overall strategy (n=27). Finally, the investment in mass media was 
limited, resulting in 20.0% (n=42 tactics) of the overall effort. 
Enrollment demographics and psycho-social factors
The mean age for the non-enrolled portion of the study population 
is 26.5 years and the average age for volunteers enrolled in the study is 
27.4 years (Table 1). There is no statistical association between gender, 
educational attainment or sexual orientation and enrollment. Race, 
however, seems to be an important factor predicting enrollment with 
white volunteers more likely to enroll than non-white volunteers (χ2, 
1df=7.65, p=0.0057). Motivation for participation had no association 
with enrollment, whereas recruitment approach had a weak association 
with enrollment (χ2, 6df=14.08, p=0.0288).
Predictive enrollment model
Multiple logistic regression analyses were used to determine the 
overall predictive ability of personal characteristics (e.g., race, gender, 
educational attainment level, and reported recruitment method) on 
the likelihood of enrollment among those eligible following clinic 
Characteristic Consented and Clinically 
Screened Participants (N=231)





Age in years 26.6 26.5 27.4
Missing 10 5 0
Gender
Female 141 96 45 
Male 90 55 35 
Missing 0 0 0
Race/Ethnicity
Asian 14 8 6
Black/African American 48 40 8
Caucasian, not Hispanic 147 89 58
Hispanic 10 4 6
Multiracial 5 5 0 
Other or Native American/Pacific Islander 4 2 2
Missing 3 3 0
Sexual Orientation
Heterosexual 187 122 65
Homosexual 20 15 5
Bisexual 13 9 4 
Missing 11 5 6
Education
Not a High School Graduate 3 2 1
High School Graduate 8 6 2
Some College, No Degree 68 47 21 
Associates Degree 6 6 0
Vocational Training 1 1 0
Bachelors Degree 99 66 33
Post-graduate Training (Masters, Doctorate or Professional Training) 37 18 19
Missing 9 5 4
Recruitment
Newspaper Ad/magazine/ Radio/Television/Billboard/Indoor/Newsletter   48 37 11
Email/Listserv/Web Site   73 52 21
Flyer/ Health Fair/ Community Event/ Educational Presentation/Special 
Event/Other/ Word of Mouth/Provider Referral/Personal Letter/Mass 
Mailing   
106 60 46
Missing 4 2 2
Motivation
Altruism 35 22 13
Compensation/Free Vaccine 75 55 20
Personal Connection to the Cause 4 3 1
Scientific or Medical Contribution 51 31 20
Other 57 34 23
Missing 9 6 3
Table 1: Characteristics of Participants in the Vaccine Trial by Those who Enrolled and Those who Did Not Enroll.
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screening. These factors were selected to ensure parsimony of model 
measures. 
Race was a significant predictor for enrollment (p=0.003). White 
participants were significantly more likely to enroll compared to 
participants who were from minority racial groups (OR=2.744; 95% 
CI=0.188-0.706). In addition, overall recruitment channel was a 
significant predictor for the enrollment (p=0.04). Those who were 
recruited by method 3 (flyer, health fair, community event, educational 
presentation, special event, word of mouth, provider referral, personal 
letter, or mass mailing) were more likely to enroll than those recruited 
through mass media messaging of method 1—newspaper ad, magazine, 
radio, television, billboard, or newsletter (p=0.01, OR=2.433, 95% 
CI=0.186-0.907).
Discussion
The 1994 NIH mandate prioritized the inclusion of women 
and minorities in research [35]. Since then, a greater emphasis has 
been placed on recruiting and retaining these populations. Recent 
evidence on minority participation in health research indicates a 
desire for information about the research activity in the community, 
greater demand to understand the relevance of the research efforts in 
addressing medical problems, and occasions to learn about clinical 
research entities and study volunteer participants [10,36]. Therefore, 
the creation of opportunities to serve these needs is necessary in order 
to effectively engage minority communities.
In this study, white participants were more likely to enroll than 
minority participants and were overrepresented in our sample. 
In Atlanta, blacks make up 32% of the population and 31% of the 
population of Georgia [37] while only constituting 10% of enrolled 
participants. Recruiting and retaining women and minorities in clinical 
research has been a challenge, which can be attributed to varying 
factors. Evidence has shown that distrust among minority populations 
of clinical research can be a strong deterrent for participation and the 
history of unethical behavior such as the Tuskegee trials continues to 
prevent minority groups from trusting the benefits of participation 
[38-40]. In addition, a lack of awareness of the study and its impact on 
the community may also serve as a factor to prevent enrollment [39]. 
It is important to continue efforts to include women and minorities in 
clinical trials and increasing the number of researchers and clinicians 
who are women or minorities will help to improve the proportion of 
those enrolled [39]. Researchers must improve how they communicate 
the intent and impact of the study and better strategize methods to 
increase the reach of that message into minority communities.
The CDC recommends the yellow fever vaccine to those who are 
traveling to countries where the disease is present, including parts of 
South America and Africa [41]. Due to the possibility of rare severe 
vaccine side effects, the CDC recommends the vaccine only for those 
who are at risk of contracting the virus [41,42]. Concerns about the 
vaccine mandated a high level of protectiveness in order to ethically 
conduct the study. As the results indicate, those who were recruited 
through direct channels, including health fairs, community events, 
referrals, and other person-to-person contact were more likely to 
enroll in the study. Recruiters were focused in their target population 
particularly on those who were traveling to areas where yellow fever is 
endemic [42,43]. The more personal methods of recruitment pursued 
a narrower audience than the mass media messaging strategies. In 
addition, the directed outreach techniques may have increased trust 
among potential participants compared to indirect outreach thus 
improving the proportion of those who enrolled in the study.
There is a need for directed strategies for vaccines that have the 
potential to cause harm, balancing the inclusion of participants who 
need the vaccine with more effective methods of outreach [43]. Directed 
strategies have the potential of immediately targeting only those who 
need the vaccine by interacting directly with populations who are at 
risk—for example, missionaries, health workers, or other travelers. 
These methods can prevent the inclusion of participants who will not 
encounter the virus and protect them from unnecessary exposure to 
the potentially severe outcomes of the vaccine. A preponderance of the 
rare, severe vaccine side effects occurs in older persons or those with 
predisposing disease conditions. In this study of healthy young adults, 
we did also include fully informed participants who had no immediate 
plans to travel to a yellow fever endemic area.
There are limitations to this study that include the small sample 
size and the directed scope of our recruitment. Furthermore, there may 
have been selection bias that differed between recruitment strategies 
since direct strategies were more easily able to target individuals who 
might require the yellow fever virus vaccine for upcoming travel 
compared to broader messaging strategies.
The main purpose of the study was to determine if the IG might 
reduce viremia, and thereby we might gain an understanding of why 
there has been an apparent increase in YFV vaccine-related side effects 
over the decade during which routine travel clinic use of IG for hepatitis 
A protection was discontinued due to the availability of the hepatitis A 
vaccine. However, we make the point in the primary study manuscript 
that for many years the YFV vaccine was co-administered with IVIG in 
travel clinics, and there was no problem with take [33]. Since this was 
an established standard of care, with no report of problem with take 
due to co-administration of IG with YFV vaccine, our IRB was fine 
with that approach. 
This study highlights the importance of ethical considerations 
and the effectiveness of direct recruitment strategies in enrolling 
participants in a study of a potentially harmful vaccine. In addition, 
researchers must continue to improve understanding of clinical trials 
in minority communities to ensure that they receive the benefits of 
participation. This can be done by continuously building trust between 
minority communities and clinical researchers as well as through more 
effective ways of communicating the benefits and aims of research to 
minority participants.
Criteria Frequency (Percent)
Age (<18 Years or >40 Years) 12 (12.5%)
Difficulty with Study Commitment 15 (15.63%)
Health Problem or medical exclusion (e.g. HIV positive) 11 (11.46%)
Lost interest 33 (34.37%)
Travel to endemic area or previous vaccination 8 (8.33%)
Other and unknown reasons 14 (14.58%)
Multiple 3 (3.13%)
Table 2: Frequency of reasons for Prescreen Ineligibility (n=96).
Criteria Frequency (Percent)
Travel to yellow fever endemic area within 2 weeks, or 
previous yellow fever vaccination
2 (7.1%)
Health Problems (positive serology, anemia, allergies, 
seizure disorder, obesity, poor venous access, elevated 
blood pressure, HCV positive, hypertension, and aortic 
valve disease)
24 (85.8%)
Other (borderline serology for other flaviviruses) 2 (7.1%)
Table 3: Causes of Clinical Screen Ineligibility (n=28).
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